

Short report

Open Access

Intrathecal delivery of PDGF produces tactile allodynia through its receptors in spinal microglia

Junya Masuda[†], Makoto Tsuda[†], Hidetoshi Tozaki-Saitoh and Kazuhide Inoue*

Address: Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Fukuoka 812-8582, Japan

Email: Junya Masuda - junyamsd@kyudai.jp; Makoto Tsuda - tsuda@phar.kyushu-u.ac.jp; Hidetoshi Tozaki-Saitoh - pdsaito@phar.kyushu-u.ac.jp; Kazuhide Inoue* - inoue@phar.kyushu-u.ac.jp

* Corresponding author †Equal contributors

Published: 11 May 2009

Received: 2 April 2009

Molecular Pain 2009, **5**:23 doi:10.1186/1744-8069-5-23

Accepted: 11 May 2009

This article is available from: <http://www.molecularpain.com/content/5/1/23>

© 2009 Masuda et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Neuropathic pain is a debilitating pain condition that occurs after nerve damage. Such pain is considered to be a reflection of the aberrant excitability of dorsal horn neurons. Emerging lines of evidence indicate that spinal microglia play a crucial role in neuronal excitability and the pathogenesis of neuropathic pain, but the mechanisms underlying neuron-microglia communications in the dorsal horn remain to be fully elucidated. A recent study has demonstrated that platelet-derived growth factor (PDGF) expressed in dorsal horn neurons contributes to neuropathic pain after nerve injury, yet how PDGF produces pain hypersensitivity remains unknown. Here we report an involvement of spinal microglia in PDGF-induced tactile allodynia. A single intrathecal delivery of PDGF B-chain homodimer (PDGF-BB) to naive rats produced a robust and long-lasting decrease in paw withdrawal threshold in a dose-dependent manner. Following PDGF administration, the immunofluorescence for phosphorylated PDGF β -receptor (p-PDGFR β), an activated form, was markedly increased in the spinal dorsal horn. Interestingly, almost all p-PDGFR β -positive cells were double-labeled with an antibody for the microglia marker OX-42, but not with antibodies for other markers of neurons, astrocytes and oligodendrocytes. PDGF-stimulated microglia *in vivo* transformed into a modest activated state in terms of their cell number and morphology. Furthermore, PDGF-BB-induced tactile allodynia was prevented by a daily intrathecal administration of minocycline, which is known to inhibit microglia activation. Moreover, in rats with an injury to the fifth lumbar spinal nerve (an animal model of neuropathic pain), the immunofluorescence for p-PDGFR β was markedly enhanced exclusively in microglia in the ipsilateral dorsal horn. Together, our findings suggest that spinal microglia critically contribute to PDGF-induced tactile allodynia, and it is also assumed that microglial PDGF signaling may have a role in the pathogenesis of neuropathic pain.

Findings

Peripheral nerve damage leads to a persistent neuropathic pain state in which innocuous stimuli elicit pain behavior

(tactile allodynia) [1-3]. Neuropathic pain might involve aberrant excitability of the nervous system, notably at the levels of the primary sensory ganglia and the dorsal horn

of the spinal cord [4-8]. There is a rapidly growing body of evidence indicating that peripheral nerve damage activates glial cells in the dorsal horn and results in changing expression and activity of various molecules [9,10]. Importantly, pharmacological, molecular and genetic manipulations of the function or expression of glial molecules have been shown to substantially influence nerve injury-induced pain behaviors and hyperexcitability of the dorsal horn pain pathway [11-15]. Therefore, signaling between neurons and glia might critically contribute to the pathologically enhanced pain processing in the dorsal horn that underlies neuropathic pain. However, the mechanisms underlying neuropathic pain caused by neuron-glia communications in the dorsal horn remain to be fully elucidated.

Platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) have served as prototypes for growth factor and receptor tyrosine kinase (RTK) function. The biologically active form of PDGF is a disulfide-bonded dimer of A-, B-, C-, or D-polypeptide chains. The PDGF isoforms (PDGF-AA, -AB, -BB, -CC, or -DD) bind two structurally related RTKs (PDGFR α and β). PDGF-AA, -BB, -AB, and -CC bind to PDGFR α , whereas PDGF-BB and -DD bind to PDGFR β [16-20]. Ligand binding induces receptor dimerization and autophosphorylation, subsequently initiates downstream signaling, and causes cellular responses such as proliferation, differentiation, survival, migration, chemotaxis, and gene expression [21,22].

Although PDGF signaling is commonly known to have essential roles during development [23], there is limited evidence for its role in the mature CNS. A recent study has shown that PDGF is expressed in dorsal horn neurons in adult mice, and that intrathecal administration of either a selective inhibitor of PDGFR phosphorylation or an antibody trapping endogenous PDGF suppresses thermal hyperalgesia and tactile allodynia after peripheral nerve injury [24]. Thus, PDGF released from dorsal horn neurons is implicated in neuropathic pain. However, how PDGF produces pain hypersensitivity remains unknown.

To investigate this, we first examined whether the intrathecal delivery of PDGF produces tactile allodynia in adult naive rats. We used the PDGF-BB isoform in all experiments in this study because PDGF-B chain expression is induced after peripheral nerve injury [25], neurons throughout the CNS contain the PDGF-B chain [26], and the PDGF-B chain activates both PDGFR α and PDGFR β [21,23]. We found that a single intrathecal administration of PDGF-BB (0.1, 1 and 10 pmol) produced marked and long-lasting tactile allodynia: the paw withdrawal threshold in response to mechanical stimulation applied to the hindpaw progressively decreased over the first 3 days, reaching the lowest in the threshold on day 3, and this

decrease persisted at least for 14 days after PDGF-BB administration ($P < 0.001$) (Figure 1). The PDGF-BB-induced tactile allodynia was dose dependent (Figure 1). In addition, we also tested the effect of AG17, a selective inhibitor for PDGFR phosphorylation, on PDGF-BB-induced allodynia. Consistent with the previous results in mice [24], intrathecal pretreatment with AG17 (100 nmol) significantly attenuated the decrease in the paw withdrawal threshold 7 days after PDGF administration (PDGF-BB + vehicle group, 1.71 ± 0.41 , $n = 4$; PDGF-BB + AG17 group, 9.43 ± 1.13 , $n = 4$; $P < 0.001$).

To identify the cell types on which intrathecally delivered PDGF-BB acts, we performed immunohistochemical experiments using an anti-phospho-Tyr1021 PDGFR β antibody (p-PDGFR β) that recognizes activated receptors [27]. The immunofluorescence for p-PDGFR β in the dorsal horns of vehicle-treated rats remained at low levels, but was markedly increased 30 min after intrathecal PDGF-BB (10 pmol) administration ($P < 0.001$) (Figure 2A, B). By double-staining with cell type-specific markers, we found that almost all p-PDGFR β -positive cells were double-labeled with OX-42 (a marker of microglia), but not with GFAP (an astrocyte marker), CC1 (an oligodendrocyte marker), MAP2 or NeuN (neuronal markers) (Figure 2C). These results indicate that activation of PDGFR β evoked by intrathecally delivered PDGF-BB occurs specifically in microglia. Consistently, both PDGFR α and PDGFR β mRNAs were detected in primary cultured microglia and in the spinal cord as well as positive




Figure 1
A single intrathecal PDGF-BB administration produces tactile allodynia. The paw withdrawal thresholds in response to mechanical stimuli were measured in rats intrathecally administered vehicle ($n = 5$) or PDGF-BB (0.1, 1 and 10 pmol, $n = 5$) just before administration (day 0) and 1, 2, 3, 5, 7, 10, and 14 days after administration. Data represent the means \pm SEM of the thresholds. *** $P < 0.001$, ** $P < 0.01$, * $P < 0.05$ vs vehicle group by repeated measures two-way ANOVA with Bonferroni post-hoc tests.




Figure 2

PDGF-BB phosphorylates its receptors in spinal microglia. (A) The immunoreactivity of phosphorylated PDGFR β protein was detected by a specific antibody for p-PDGFR β 30 min after intrathecal administration of vehicle or PDGF-BB (10 pmol) in the L5 spinal dorsal horn. Scale bar, 200 μ m. (B) The intensity of p-PDGFR β immunofluorescence was quantified in the dorsal horn region of vehicle treated rats and PDGF-BB treated rats. Data represent the means \pm SEM of the immunofluorescence intensity (n = 5). ***P < 0.001 vs vehicle by Student's t-test. (C) Double immunofluorescence labeling of the dorsal horn 30 min after intrathecal PDGF-BB administration with p-PDGFR β (green) and cell markers (red); OX-42, a microglia marker; GFAP, an astrocytes marker; CC1, an oligodendrocytes marker; NeuN and MAP2, neurons markers. Scale bars, 20 μ m. (D) PDGFR α (116 bp) and PDGFR β (145 bp) mRNA expression in primary microglia by RT-PCR analysis. Spinal cord, cerebral cortex, and spleen are positive controls. (E) Triple immunofluorescence labeling of p-PDGFR β (green) with OX-42 (red) and DAPI (blue), a nuclear marker, in primary microglia treated with PBS as a control or PDGF-BB (50 ng/ml) for 10 min. Scale bar, 20 μ m.

control tissues (cerebral cortex and spleen) (Figure 2D). Furthermore, applying PDGF-BB (50 ng/ml) to primary cultured microglial cells enhanced the immunofluorescence for p-PDGFR β (Figure 2E).

Because the half life of PDGF *in vivo* is extremely short [28], it is predicted that PDGF-induced long-lasting tactile allodynia might be due to plastic changes in the spinal cord, especially in microglia. To investigate the status of microglia in the dorsal horn after PDGF stimulation, we performed immunohistochemical analysis using the microglia marker Iba1. After PDGF-BB (10 pmol) administration, the number of Iba1-positive cells in the dorsal horn was significantly increased on day 3 and day 7 compared with vehicle-treated controls ($P < 0.01$) (Figure 3A, B). Iba1-positive microglia in the dorsal horns of PDGF-BB-administered rats also showed an increase in Iba1 labeling and a tendency toward a hypertrophied morphology (Figure 3C). We also observed an increase in the level of expression of the proinflammatory cytokine interleukin-1 β (IL-1 β) ($P < 0.05$) (Figure 3D). Because these changes are consistent with the criteria for activated microglia *in vivo*, it is suggested that spinal microglia are activated by PDGF-BB.

To examine whether microglia are involved in PDGF-BB-induced tactile allodynia, we tested the effect of minocycline, which inhibits microglia activation [29,30], on the decrease in the paw withdrawal threshold after PDGF-BB administration. Daily intrathecal administration of minocycline (100 μ g) from one day before PDGF-BB (10 pmol) administration significantly suppressed the decrease in paw withdrawal threshold ($P < 0.05$, day 3; $P < 0.01$, other testing days) (Figure 3E). This finding suggests that spinal microglia are involved in PDGF-BB-induced tactile allodynia. The mechanisms underlying the anti-allodynic effect of minocycline remains unclear, but we found that minocycline did not inhibit PDGF-induced PDGFR β phosphorylation in the dorsal horn (Figure 3F), indicating that minocycline does not directly interrupt the PDGF binding to the PDGFR β and PDGFR β dimerization and autophosphorylation. Thus, it is conceivable that minocycline may produce its anti-allodynic effect through inhibiting the downstream consequences of PDGFR β phosphorylation in microglia including p38 mitogen-activated protein kinase that is an important signaling molecule in tactile allodynia [11,15] and is also known as one of targets of minocycline [31,32].

Purinergic receptors expressed in microglia (P2X₄, P2X₇ and P2Y₁₂) are implicated in neuropathic pain [12,13,33,34]. Thus, we examined the role of these receptors in PDGF-BB-induced allodynia. After intrathecal PDGF-BB (10 pmol) administration, the level of mRNA expression of P2X₄ receptor in the spinal cord was signifi-

cantly increased on day 3 ($P < 0.05$) (Figure 4A). By contrast, the mRNA levels of P2X₇ and P2Y₁₂ receptors were not changed. Furthermore, intrathecally administered TNP-ATP (30 nmol), an antagonist of P2X receptor subtypes P2X₁₋₄ receptors, produced a significant attenuation of the decreased paw withdrawal threshold on day 7 after PDGF-BB (10 pmol) administration ($P < 0.05$) (Figure 4B). Considering that the anti-allodynic effect of TNP-ATP was weak, these results suggest that P2X₄ receptors in the spinal cord are involved, at least in part, in the PDGF-BB-induced tactile allodynia.

Activation of PDGFRs in the spinal cord is implicated in tactile allodynia after peripheral nerve injury [24]. Thus, we determined the type of cells in which PDGFR β activation occurs under a neuropathic pain condition. In contrast to the contralateral dorsal horn, where p-PDGFR β immunofluorescence was low, we observed strong p-PDGFR β immunofluorescence in the dorsal horn ipsilateral to the nerve injury; the level of p-PDGFR β immunofluorescence in individual cells in this region was also much higher than that in individual cells in the dorsal horn contralateral to the nerve injury ($P < 0.01$) (Figure 5A, B). Furthermore, almost all p-PDGFR β -positive cells were also labeled for the microglia marker OX-42 (Figure 5C). These results indicate that PDGFR β activation in the dorsal horn occurs exclusively in microglia after nerve injury. How PDGFR activity is enhanced remains unclear, but we examined the time course for changes in the expression levels of PDGFR mRNAs after nerve injury and found no significant change during the period from 1 day to 14 days post-nerve injury (Figure 5D). It is thus possible that the enhanced PDGFR activity might be due to an increase in the level of endogenous PDGF within the dorsal horn after nerve injury, as suggested by a previous study [24]. Consistently, low levels of PDGFR β phosphorylation in the dorsal horns of normal rats (Figure 2A) and in the contralateral dorsal horns of nerve-injured rats (Figure 5A) were observed. In the adult spinal cord, PDGF has been shown to be expressed in dorsal horn neurons [24]. It is thus assumed that PDGF might be a candidate for signaling molecules between neurons and microglia, thereby producing tactile allodynia, although further investigations are needed to determine the pattern and change in the expression of endogenous PDGFR β ligands in the dorsal horn after nerve injury.

PDGFRs in the CNS have been previously reported to be expressed in O-2A progenitor cells, oligodendrocytes, and neurons [35-38]. In the present study, by showing that acute PDGF stimulation *in vivo* in adult rats induced PDGFR β phosphorylation specifically in microglia, in addition to our results in *in vitro* experiments using cultured microglia, we provide the first evidence that microglia are the predominant cell type expressing functional PDGFR β s in




Figure 3
Microglial activation is involved in PDGF-BB-induced tactile allodynia. (A) The L5 spinal cord segments from PDGF-BB-administered rats at day 3 and 7 were subjected to immunohistochemistry using an anti-Iba1 antibody. Scale bar, 200 μ m. (B) The number of Iba1-positive cells was counted in the dorsal horn. Data are means \pm SEM of the cell number (day 3, n = 4; day 7, n = 3). ** P < 0.01 vs vehicle by Student's *t*-test. (C) The magnified images of Iba1 staining at day 3. Scale bar, 20 μ m. (D) Total RNA extracted from the L5 spinal dorsal horn 3 days after PDGF administration was subjected to quantitative analysis of interleukin-1 β (IL-1 β) mRNA expression by real-time RT-PCR. Data are means \pm SEM of the fold change over vehicle control (n = 3). * P < 0.05 vs vehicle by Student's *t*-test. (E) The paw withdrawal thresholds of PDGF-BB (10 pmol)-administered rats were measured in a combined administration group with minocycline (100 μ g, n = 4) or vehicle (PBS, n = 4). Minocycline or vehicle was intrathecally administered daily from one day before PDGF-BB administration. Data are means \pm SEM of the thresholds. *** P < 0.001, ** P < 0.01 vs before PDGF-BB administration; ## P < 0.01, # P < 0.05 vs PDGF 10 pmol + vehicle group by Student's *t*-test. (F) Immunofluorescence for p-PDGFR β in the L5 spinal dorsal horn 30 min after PDGF-BB (10 pmol) administration in minocycline- or vehicle-pre-administered rats. Minocycline or vehicle was intrathecally administered one day and 30 min before PDGF-BB administration. Scale bar, 200 μ m.

the spinal cord. We further revealed that spinal microglia may mediate tactile allodynia caused by intrathecal administration of PDGF. Recently, Narita et al. [24] have shown that inhibiting PDGFR phosphorylation results in suppression of tactile allodynia after peripheral nerve injury, implying a crucial role for PDGF signaling in neuropathic pain. Notably, following peripheral nerve injury, a marked enhancement of PDGFR β phosphorylation in dorsal horn microglia also occurred in a cell type-specific manner, indicating that spinal microglia may be crucial for PDGFR-mediated tactile allodynia under neuropathic pain conditions. It remains unknown how PDGF-stimulated microglia modulate pain processing in the dorsal horn, but we found an increase in the expression of IL-1 β mRNA in the dorsal horn after PDGF administration. IL-1 β enhances C-fiber-evoked responses in wide-dynamic-range dorsal horn neurons [39], enhances NMDA receptor-mediated Ca²⁺ responses [40], and decreases GABA_A receptor-mediated currents [41]. A recent study has also demonstrated a powerful role for this cytokine in excitatory and inhibitory synaptic transmission and an effect of this cytokine on neuronal activity in superficial dorsal horn neurons [42,43].

Therefore, IL-1 β may be a candidate intermediary molecule between PDGF-stimulated microglia and dorsal horn neurons that contributes to central hypersensitization. Further investigation using microglia-specific IL-1 β -knockout mice will clarify this issue.

Methods

Animals

Male Wistar rats (250–280 g, Japan SLC) were used. Rats were housed at a constant temperature of 23 \pm 1 $^{\circ}$ C with a 12 h light-dark cycle (light on 8:00 to 20:00) and fed food and water *ad libitum*. All of the animals used in the present study were obtained, housed, cared for, and used in accordance with the guidelines of Kyushu University.

Microglia culture

Rat primary cultured microglia was prepared according to the method described previously [44]. In brief, the mixed glial culture was prepared from neonatal Wistar rats and maintained for 9–15 days in DMEM with 10% FBS. Microglia were obtained as floating cells over the mixed glial culture. The floating cells were collected by gentle shaking and transferred to culture dishes for each experiment.

Drug administration

Under 2% isoflurane anesthesia, rats were implanted with a 32 gauge intrathecal catheter (ReCathCo, Allison Park, PA, USA) in the lumbar enlargement (close to L4-5 segments) for intrathecal drug administration. The catheter placement was verified by the observation of hindlimb




Figure 4
ATP receptors relation to PDGF-BB-induced allodynia. (A) Total RNA extracted from the L5 spinal cord on day 3 after PDGF-BB (10 pmol) administration was subjected to quantitative analysis of P2X₄, P2X₇, and P2Y₁₂ receptors mRNA expression by real-time RT-PCR. Data are means \pm SEM of the fold change over vehicle control (n = 5). *P < 0.01 vs vehicle by Student's *t*-test. (B) The paw withdrawal thresholds before (pre) and 7 days (day7) after intrathecal PDGF-BB (10 pmol) administration (n = 8). Then TNP-ATP (30 nmol) and vehicle (PBS) was intrathecally administered on day 7 and the changes in the paw withdrawal thresholds were measured (n = 4). Data are means \pm SEM of the thresholds. ###P < 0.001 vs pre, *P < 0.05 vs vehicle group by Student's *t*-test.

paralysis induced by intrathecal administration of lidocaine (2%, 5 μ l). Rats that failed to cause paralysis were excluded from the experiments. A recombinant human platelet-derived growth factor, PDGF-BB (0.1, 1 and 10 pmol/10 μ l PBS; Millipore Bioscience Research Reagents, Temecula, California, USA), or PBS (10 μ l, as a vehicle control) was intrathecally administered in naive rats. AG 17 [100 nmol/10 μ l PBS containing dimethylsulfoxide (6%: final concentration); Calbiochem] or PBS containing 6% dimethylsulfoxide (10 μ l, as a vehicle control) was intrathecally administered 30 min before PDGF-BB (10 pmol/10 μ l PBS) administration. Minocycline (100 μ g/10 μ l PBS; Sigma) or PBS (10 μ l, as a vehicle control) was intrathecally administered once a day from 1 day before PDGF-BB (10 pmol/10 μ l PBS) administration. 2',3'-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate, TNP-ATP (30 nmol/10 μ l PBS; Sigma), or PBS (10 μ l, as a vehi-




Figure 5
Immunofluorescence of phosphorylated PDGF β -receptors and expression of PDGF receptor mRNAs in rats after nerve injury. (A) The immunoreactivity for p-PDGFR β was detected in the L5 spinal dorsal horn 4 days after nerve injury. Scale bar, 200 μ m. (B) The intensity of p-PDGFR β immunofluorescence was quantified in the dorsal horn region of contralateral side (contra) and ipsilateral side (ipsi) of nerve injured rats. Data represent the means \pm SEM of the immunofluorescence intensity (n = 3). **P < 0.01 vs contra by Student's *t*-test. (C) Double immunofluorescence labeling of p-PDGFR β (green) with OX-42 (red), a microglia marker. Scale bars, 20 μ m. (D) Total RNA extracted from the L5 spinal cords of naive rats and peripheral nerve injured rats was subjected to quantitative analysis of PDGFR mRNA expression by real-time RT-PCR. Data are means \pm SEM of the percentage over the naive value (ipsilateral side/contralateral side, n = 5).

cle control) was intrathecally administered on day 7 after PDGF-BB (10 pmol/10 μ l PBS) administration.

Neuropathic pain model and Behavioral tests

The left L5 spinal nerve of rats was tightly ligated with 5-0 silk suture and cut just distal to the ligature under 2% iso-

flurane anesthesia [12,45]. To assess the level of tactile allodynia, rats were placed individually in a wire mesh cage and habituated for 30–60 min to allow acclimatization to the new environment. From below the mesh floor, calibrated von Frey filaments (0.4–15 g; North Coast Medical, Morgan Hill, California, USA) were applied to the mid-plantar surface of the hindpaw. The 50% paw withdrawal threshold was determined using the up-down method [46].

Immunohistochemistry

The rats used in the experiments were deeply anesthetized with pentobarbital (100 mg/kg, i.p.) and perfused transcardially with ice-cold PBS, followed by ice-cold 4% paraformaldehyde in PBS. The L5 segments of the lumbar spinal cord were removed, post-fixed in the same fixative for 4 h at 4°C, and placed in 30% sucrose solution for 24 h at 4°C. Transverse spinal cord sections (30 µm) were sliced by a Leica CM 1850 cryostat and incubated in a blocking solution (3% normal goat serum) for 2 h at room temperature, and then incubated for 48 h at 4°C with the primary antibodies against phospho-PDGFRβ (rabbit polyclonal anti-phospho-Tyr1021 of PDGFRβ, 1:2000, Santa Cruz Biotechnology, Santa Cruz, CA, USA), or cell markers; microglia, OX-42 (mouse monoclonal anti-OX-42, 1:1000, Serotec, Oxford, UK) and ionized calcium-binding adapter molecule-1 (Iba1) (rabbit polyclonal anti-Iba1, 1:2000, Wako, Osaka, Japan); astrocytes, glial fibrillary acidic protein (GFAP) (mouse monoclonal anti-GFAP, 1:2000, Millipore Bioscience Research Reagents); oligodendrocytes, CC-1 (mouse monoclonal anti-APC, 1:500, Millipore Bioscience Research Reagents); neurons, neuronal nuclei (NeuN) (mouse monoclonal anti-NeuN, 1:200, Millipore Bioscience Research Reagents) and microtubule-associated protein-2 (MAP2) (mouse monoclonal anti-MAP2, 1:500, Millipore Bioscience Research Reagents). The sections were then washed and incubated for 3 h at room temperature with the fluorescent conjugated secondary antibodies (goat anti-rabbit IgG-conjugated Alexa Fluor 488 or goat anti-mouse IgG-conjugated Alexa Fluor 546, 1:1000, Invitrogen, Carlsbad, CA, USA). The sections were mounted with Vectashield (Vector Laboratories, Burlingame, CA, USA). Fluorescent images were obtained with a confocal microscope (LSM 5 Pascal; Carl Zeiss, Jena, Germany) and analyzed with Zeiss LSM Image Browser (Carl Zeiss). For quantitative assessment of the immunofluorescence staining, the spinal dorsal horn regions were outlined and the immunofluorescence intensity of the p-PDGFRβ was determined as the average pixel intensity within the field.

Immunocytochemistry

Primary microglial cells were seeded on aminopropyltriethoxysilane-coated glass (Matsunami, Osaka, Japan) at 5

× 10⁴ cells/well and incubated for 1 h. After the culture media were replaced with serum-free media, cells were incubated for 2 h and subsequently treated with PBS as a control or 50 ng/ml PDGF-BB for 10 min [47], and then fixed in 3.7% formaldehyde in PBS for 30 min at 25°C. The cells were permeabilized and blocked by incubating them with blocking solution (3% normal goat serum and 0.3% Triton X-100 in PBS) for 15 min at 25°C, and then incubated overnight at 4°C with the primary antibodies against phospho-PDGFRβ (1:400) and OX-42 (1:1000). After washing, the cells were incubated for 1 h with appropriate fluorescent-conjugated secondary antibodies (goat anti-rabbit IgG-conjugated Alexa Fluor 488 or goat anti-mouse IgG-conjugated Alexa Fluor 546, 1:1000) and coverslipped in Vectashield containing 4',6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA, USA). Fluorescent images were obtained and analyzed as mentioned above.

Real-Time Quantitative RT-PCR

The rats used in the experiments were deeply anesthetized with pentobarbital (100 mg/kg, i.p.) and perfused transcardially with ice-cold PBS. The L5 segments of lumbar spinal cord were removed immediately and were subjected to total RNA extraction using Trisure (Biolone, Danwon-Gu, South Korea) according to the protocol of the manufacturer and purified with RNeasy mini plus kit (Qiagen, Valencia, CA, USA). The amount of total RNA was quantified by measuring OD₂₆₀ using a Nanodrop spectrophotometer (Nanodrop, Wilmington, DE, USA). For reverse transcription with random 6-mer primers, 100 ng of total RNA was transferred to the reaction with Prime Script reverse transcriptase (Takara, Kyoto, Japan). Quantitative PCR was performed with Premix Ex Taq (Takara) using a 7500 real-time PCR system (Applied Biosystems, Foster City, CA, USA) according to protocol of the manufacturer, and the data were analyzed by 7500 System SDS Software 1.3.1 (Applied Biosystems) using the standard curve method. Expression levels were normalized to the values for glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The TaqMan probes and primers for interleukin-1β (IL-1β) (Taqman probe, 5'-FAM-TTCTCCACCTCAATGGACAGAACATAAGCCA-TAMRA-3'; forward primer, AAATGCCCTCGTGCTGTCTGA; reverse primer, GT CGTTGCTTGCTCTCCTTGATC), P2X₄ receptor (P2X₄R) (Taqman probe, 5'-FAM-AGGAG-GAAAACCTCCTCTTCAT CATGACCA-TAMRA-3'; forward primer, TGGCGGACTATGTGATTCCA; reverse primer, GGTTACGGTGACGATCATG), P2X₇ receptor (P2X₇R) (Taqman probe, 5'-FAM-AAAGCCTTCGGCGT-GCGTTTTGA-TAMRA-3'; forward primer, CAT-GGAAAAGCGGACATTGA; reverse primer, CCAGTGCCAAAAACCAGGAT), P2Y₁₂ receptor (P2Y₁₂R) (Taqman probe, 5'-FAM-CACCAGACCATTTAAACTTC-CAGCCCC-TAMRA-3'; forward primer, TAACCATTGAC-CGATACCTGAAGA; reverse primer, TTCGCACCCAAAAG

ATTGC), PDGF receptor α -subtype (PDGFR α) (Taqman probe, 5'-FAM-ATATTCTCCCTTGGTGGCACACCCTACC-TAMRA-3'; forward primer, ACGTCTGGTCTTATGGCGT-TCT; reverse primer, CATCCTGTATCCGCTCTTGATCT), and PDGFR β (Taqman probe, 5'-FAM-AACGACTCAC-CAGTGCTCAGCTACACAGAC-TAMRA-3'; forward primer, GTCCCATCTGCCCTGAAA; reverse primer, GGTCTCG-GTGAACACAGTTCTAG), as well as the probe and primer for GAPDH, were obtained from Applied Biosystems.

Statistical Analysis

All data are presented as means \pm SEM. The statistical analyses of the results were evaluated by using the Student's *t* test or two-way repeated measures ANOVA with Bonferroni post tests.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

JM performed the majority of experiments, analyzed the data, and drafted the manuscript; MT designed and supervised the experiments, and wrote the manuscript; HST supervised some experiments; KI coordinated the project, supervised the experiments, helped to interpret the data, edited the manuscript. All authors discussed the results and commented on the manuscript.

Acknowledgements

This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to MT, KI).

References

1. Woolf CJ, Mannion RJ: **Neuropathic pain: aetiology, symptoms, mechanisms, and management.** *Lancet* 1999, **353**:1959-1964.
2. Nicholson B: **Differential diagnosis: nociceptive and neuropathic pain.** *Am J Manag Care* 2006, **12**:S256-262.
3. Scholz J, Woolf CJ: **Can we conquer pain?** *Nat Neurosci* 2002, **5**(Suppl):1062-1067.
4. Woolf CJ: **Evidence for a central component of post-injury pain hypersensitivity.** *Nature* 1983, **306**:686-688.
5. Pol AN van den, Obrietan K, Chen G: **Excitatory actions of GABA after neuronal trauma.** *J Neurosci* 1996, **16**:4283-4292.
6. Moore KA, Kohno T, Karchewski LA, Scholz J, Baba H, Woolf CJ: **Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord.** *J Neurosci* 2002, **22**:6724-6731.
7. Obata K, Noguchi K: **MAPK activation in nociceptive neurons and pain hypersensitivity.** *Life Sci* 2004, **74**:2643-2653.
8. Zhou XF, Deng YS, Chie E, Xue Q, Zhong JH, McLachlan EM, Rush RA, Xian CJ: **Satellite-cell-derived nerve growth factor and neurotrophin-3 are involved in noradrenergic sprouting in the dorsal root ganglia following peripheral nerve injury in the rat.** *Eur J Neurosci* 1999, **11**:1711-1722.
9. Tsuda M, Inoue K, Salter MW: **Neuropathic pain and spinal microglia: a big problem from molecules in "small" glia.** *Trends Neurosci* 2005, **28**:101-107.
10. Watkins LR, Milligan ED, Maier SF: **Glial activation: a driving force for pathological pain.** *Trends Neurosci* 2001, **24**:450-455.
11. Tsuda M, Mizokoshi A, Shigemoto-Mogami Y, Koizumi S, Inoue K: **Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury.** *Glia* 2004, **45**:89-95.
12. Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, Inoue K: **P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury.** *Nature* 2003, **424**:778-783.
13. Tozaki-Saitoh H, Tsuda M, Miyata H, Ueda K, Kohsaka S, Inoue K: **P2Y12 receptors in spinal microglia are required for neuropathic pain after peripheral nerve injury.** *J Neurosci* 2008, **28**:4949-4956.
14. Zhuang ZY, Kawasaki Y, Tan PH, Wen YR, Huang J, Ji RR: **Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine.** *Brain Behav Immun* 2007, **21**:642-651.
15. Jin SX, Zhuang ZY, Woolf CJ, Ji RR: **p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain.** *J Neurosci* 2003, **23**:4017-4022.
16. Li X, Ponten A, Aase K, Karlsson L, Abramsson A, Uutela M, Backstrom G, Hellstrom M, Bostrom H, Li H, et al.: **PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor.** *Nat Cell Biol* 2000, **2**:302-309.
17. LaRochelle WJ, Jeffers M, McDonald WF, Chillakuru RA, Giese NA, Lokker NA, Sullivan C, Boldog FL, Yang M, Vernet C, et al.: **PDGF-D, a new protease-activated growth factor.** *Nat Cell Biol* 2001, **3**:517-521.
18. Claesson-Welsh L, Eriksson A, Westermark B, Heldin CH: **cDNA cloning and expression of the human A-type platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-type PDGF receptor.** *Proc Natl Acad Sci USA* 1989, **86**:4917-4921.
19. Matsui T, Heidarani M, Miki T, Popescu N, La Rochelle W, Kraus M, Pierce J, Aaronson S: **Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes.** *Science* 1989, **243**:800-804.
20. Yarden Y, Escobedo JA, Kuang WJ, Yang-Feng TL, Daniel TO, Tremble PM, Chen EY, Ando ME, Harkins RN, Francke U, et al.: **Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors.** *Nature* 1986, **323**:226-232.
21. Andrae J, Gallini R, Betsholtz C: **Role of platelet-derived growth factors in physiology and medicine.** *Genes Dev* 2008, **22**:1276-1312.
22. Heldin CH, Ostman A, Ronnstrand L: **Signal transduction via platelet-derived growth factor receptors.** *Biochim Biophys Acta* 1998, **1378**:F79-113.
23. Hoch RV, Soriano P: **Roles of PDGF in animal development.** *Development* 2003, **130**:4769-4784.
24. Narita M, Usui A, Niiikura K, Nozaki H, Khotib J, Nagumo Y, Yajima Y, Suzuki T: **Protease-activated receptor-1 and platelet-derived growth factor in spinal cord neurons are implicated in neuropathic pain after nerve injury.** *J Neurosci* 2005, **25**:10000-10009.
25. Oya T, Zhao YL, Takagawa K, Kawaguchi M, Shirakawa K, Yamauchi T, Sasahara M: **Platelet-derived growth factor-b expression induced after rat peripheral nerve injuries.** *Glia* 2002, **38**:303-312.
26. Sasahara M, Fries JW, Raines EW, Gown AM, Westrum LE, Frosch MP, Bonthron DT, Ross R, Collins T: **PDGF B-chain in neurons of the central nervous system, posterior pituitary, and in a transgenic model.** *Cell* 1991, **64**:217-227.
27. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Hamilton SR, Fidler IJ: **Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential.** *Int J Cancer* 2006, **119**:2567-2574.
28. Bowen-Pope DF, Malpass TW, Foster DM, Ross R: **Platelet-derived growth factor in vivo: levels, activity, and rate of clearance.** *Blood* 1984, **64**:458-469.
29. Ledebner A, Sloane EM, Milligan ED, Frank MG, Mahony JH, Maier SF, Watkins LR: **Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation.** *Pain* 2005, **115**:71-83.
30. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J: **Minocycline, a tetracycline derivative, is neuroprotective against**

- excitotoxicity by inhibiting activation and proliferation of microglia.** *J Neurosci* 2001, **21**:2580-2588.
31. Hua XY, Svensson CI, Matsui T, Fitzsimmons B, Yaksh TL, Webb M: **Intrathecal minocycline attenuates peripheral inflammation-induced hyperalgesia by inhibiting p38 MAPK in spinal microglia.** *Eur J Neurosci* 2005, **22**:2431-2440.
 32. Piao ZG, Cho IH, Park CK, Hong JP, Choi SY, Lee SJ, Lee S, Park K, Kim JS, Oh SB: **Activation of glia and microglial p38 MAPK in medullary dorsal horn contributes to tactile hypersensitivity following trigeminal sensory nerve injury.** *Pain* 2006, **121**:219-231.
 33. Kobayashi K, Yamanaka H, Fukuoka T, Dai Y, Obata K, Noguchi K: **P2Y12 receptor upregulation in activated microglia is a gateway of p38 signaling and neuropathic pain.** *J Neurosci* 2008, **28**:2892-2902.
 34. Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, Egerton J, Murfin M, Richardson J, Peck WL, et al.: **Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain.** *Pain* 2005, **114**:386-396.
 35. Smits A, Kato M, Westermark B, Nister M, Heldin CH, Funa K: **Neurotrophic activity of platelet-derived growth factor (PDGF): Rat neuronal cells possess functional PDGF beta-type receptors and respond to PDGF.** *Proc Natl Acad Sci USA* 1991, **88**:8159-8163.
 36. Yeh HJ, Silos-Santiago I, Wang YX, George RJ, Snider WD, Deuel TF: **Developmental expression of the platelet-derived growth factor alpha-receptor gene in mammalian central nervous system.** *Proc Natl Acad Sci USA* 1993, **90**:1952-1956.
 37. Oumesmar BN, Vignais L, Baron-Van Evercooren A: **Developmental expression of platelet-derived growth factor alpha-receptor in neurons and glial cells of the mouse CNS.** *J Neurosci* 1997, **17**:125-139.
 38. Raff MC: **Glial cell diversification in the rat optic nerve.** *Science* 1989, **243**:1450-1455.
 39. Reeve AJ, Patel S, Fox A, Walker K, Urban L: **Intrathecal administration of endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to noxious stimuli in the rat.** *Eur J Pain* 2000, **4**:247-257.
 40. Viviani B, Bartesaghi S, Gardoni F, Vezzani A, Behrens MM, Bartfai T, Binaglia M, Corsini E, Di Luca M, Galli CL, Marinovich M: **Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases.** *J Neurosci* 2003, **23**:8692-8700.
 41. Wang S, Cheng Q, Malik S, Yang J: **Interleukin-1beta inhibits gamma-aminobutyric acid type A (GABA(A)) receptor current in cultured hippocampal neurons.** *J Pharmacol Exp Ther* 2000, **292**:497-504.
 42. Ikeda H, Tsuda M, Inoue K, Murase K: **Long-term potentiation of neuronal excitation by neuron-glia interactions in the rat spinal dorsal horn.** *Eur J Neurosci* 2007, **25**:1297-1306.
 43. Kawasaki Y, Zhang L, Cheng JK, Ji RR: **Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord.** *J Neurosci* 2008, **28**:5189-5194.
 44. Nakajima K, Shimojo M, Hamanoue M, Ishiura S, Sugita H, Kohsaka S: **Identification of elastase as a secretory protease from cultured rat microglia.** *J Neurochem* 1992, **58**:1401-1408.
 45. Kim SH, Chung JM: **An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat.** *Pain* 1992, **50**:355-363.
 46. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: **Quantitative assessment of tactile allodynia in the rat paw.** *J Neurosci Methods* 1994, **53**:55-63.
 47. Park CS, Schneider IC, Haugh JM: **Kinetic analysis of platelet-derived growth factor receptor/phosphoinositide 3-kinase/Akt signaling in fibroblasts.** *J Biol Chem* 2003, **278**:37064-37072.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

